1yr
1yr
CDK4/6 inhibitors combined with endocrine therapy significantly improve efficacy in HR+/HER2- advanced breast cancer first-line treatment. Adding immune checkpoint inhibitors enhances outcomes in second-line settings, though more trials are needed.
1yr
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38326452/
Individual trials of abemaciclib, palbociclib, and ribociclib show a similar impact on progression-free survival yet differing statistical significance for overall survival (OS). A robust comparative evaluation of OS, safety, and...
A network meta-analysis of CDK4/6 inhibitors in ER-positive/HER2-negative breast cancer shows no OS difference but highlights safety variations, with abemaciclib having higher GI toxicity and treatment discontinuation rates.
1yr
Male Breast Cancer (MBC) - A Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38058163/
Males account for 1% of all cases of breast cancer. With the aging of the world's population, the disease has exhibited a rise in incidence in recent decades. Male breasts...
This review discusses male breast cancer's rising incidence, clinical features, and management challenges, emphasizing the importance of awareness and research due to its rarity and similarities to female cases.
1yr
Breast cancer organoids derived from patients: A platform for tailored drug screening - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37709150/
Breast cancer stands as the most prevalent and heterogeneous malignancy affecting women globally, posing a substantial health concern. Enhanced comprehension of tumor pathology and the development of novel therapeutics are...
This review highlights the potential of breast cancer organoids as advanced in vitro models, emphasizing their advantages in precision medicine, drug innovation, and disease modeling through enhanced tissue mimicry and genetic stability.